MimiVax Stock

MimiVax is a developer of immunotherapeutic vaccines and targeted therapies used to control tumor growth and recurrence.

Sign up today and learn more about MimiVax Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About MimiVax Stock

MimiVax is a privately-held, clinical-stage biotechnology company that focuses on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. Its vaccines use survivin-targeting technology to target a cell-survival protein present in most cancers that enable healthcare providers to cure their patients. The company was founded in 2012 and is headquartered in Buffalo, New York.

Funding History

August 2015$1.6M
November 2019$10.0M
December 2021$5.0M

Management

Board Member, Co-founder, and General Counsel

Scott E. Friedman

Chief Medical Officer

Robert Fenstermaker

Chief Scientific Officer

Michael Ciesielski

CEO

Michael Ciesielski

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo